Koyfin Home > Directory > Health Care > Antares Pharma > EBITDA Margin

Antares Pharma EBITDA Margin Chart (ATRS)

Antares Pharma annual/quarterly EBITDA Margin from 2000 to 2018. An EBITDA margin is a measurement of a company's earnings before interest, taxes, depreciation, and amortization as a percentage of its total revenue.
  • Antares Pharma EBITDA Margin for the quarter ending December 12, 2018 was $-27m a -45.38% increase of 12m year over year
  • Antares Pharma EBITDA Margin for the last 12 months ending December 12, 2018 was $-22m a -22.41% increase of 5m year over year
  • Antares Pharma Annual EBITDA Margin for 2018 was $-22m a -17.87% increase of 4m from 2017
  • Antares Pharma Annual EBITDA Margin for 2017 was $-26m a -61.94% increase of 16m from 2016
  • Antares Pharma Annual EBITDA Margin for 2016 was $-43m a 2.91% decrease of -1m from 2015
Other Margins & Efficiency Metrics:
  • Antares Pharma Return on Capital % for the quarter ending December 12, 2018 was -25.15 a -0.12% increase of 0.03 year over year
  • Antares Pharma Return on Equity % for the quarter ending December 12, 2018 was 77.43 a 203.55% increase of 157.61 year over year
View Chart On Koyfin

Quarterly ATRS EBITDA Margin Data

12/2018$-27m
09/2018$-4m
06/2018$-23m
03/2018$-39m
12/2017$-24m
09/2017$-29m
06/2017$-17m
03/2017$-36m
12/2016$-26m
09/2016$-42m

Annual ATRS EBITDA Margin Data

2018$-22m
2017$-26m
2016$-43m
2015$-41m
2014$-128m
2013$-99m
2012$-50m
2011$-26m
2010$-46m
2009$-114m